Get the Stockscreener App
4.56
1.79%
0.08
After Hours:
4.51
-0.05
-1.10%
Certara Inc stock is traded at $4.56, with a volume of 3.06M.
It is up +1.79% in the last 24 hours and down -26.69% over the past month.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
See More
Previous Close:
$4.48
Open:
$4.48
24h Volume:
3.06M
Relative Volume:
0.81
Market Cap:
$709.37M
Revenue:
$418.84M
Net Income/Loss:
$-1.60M
P/E Ratio:
-442.72
EPS:
-0.0103
Net Cash Flow:
$69.77M
1W Performance:
-11.11%
1M Performance:
-26.69%
6M Performance:
-43.91%
1Y Performance:
-61.62%
1-Day Range:
$4.46
$4.67
1-Week Range:
$4.45
$5.44
52-Week Range:
$4.45
$13.88
Certara Inc Stock (CERT) Company Profile
Name
Certara Inc
Sector
Industry
Phone
(415) 237-8272
Address
4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR
Compare CERT vs VEEV, BTSG, TEM, HQY, HNGE
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CERT
Certara Inc
|
4.56 | 696.93M | 418.84M | -1.60M | 69.77M | -0.0103 |
VEEV
Veeva Systems Inc
|
163.85 | 25.93B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
56.18 | 11.23B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
43.62 | 7.89B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
83.04 | 6.89B | 1.31B | 215.20M | 408.32M | 2.4627 |
HNGE
Hinge Health Inc
|
54.71 | 4.22B | 587.86M | -425.10M | 0 | -5.691 |
Certara Inc Stock (CERT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-27-26 | Downgrade | Craig Hallum | Buy → Hold |
| Jan-06-26 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-21-25 | Initiated | Rothschild & Co Redburn | Buy |
| Nov-13-25 | Initiated | BMO Capital Markets | Market Perform |
| Sep-29-25 | Initiated | Craig Hallum | Buy |
| Jul-03-25 | Resumed | Morgan Stanley | Equal-Weight |
| May-08-25 | Upgrade | Barclays | Equal Weight → Overweight |
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Upgrade | UBS | Neutral → Buy |
| Apr-10-24 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Apr-04-24 | Initiated | JMP Securities | Mkt Perform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | UBS | Neutral |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Aug-22-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-10-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-23 | Initiated | Stephens | Overweight |
| Apr-03-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-08-22 | Initiated | Berenberg | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-01-22 | Initiated | Piper Sandler | Overweight |
| Jan-11-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Jul-23-21 | Initiated | Robert W. Baird | Outperform |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-06-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Neutral |
| Jan-05-21 | Initiated | Jefferies | Hold |
| Jan-05-21 | Initiated | William Blair | Outperform |
View All
Certara Inc Stock (CERT) Latest News
Certara to Participate in Upcoming Investor Conferences - The Manila Times
Certara schedules RBC, William Blair and Jefferies investor appearances - Stock Titan
Certara, Inc. (CERT) Q1 earnings miss estimates - MSN
Certara says AI investments will drive long-term growth – but traders are focused on one warning - MSN
Certara expects $395M-$405M 2026 revenue following medical writing divestiture - MSN
Certara (CERT) shares slide after weak full-year guidance overshadows revenue beat - MSN
Certara stock (US1567671046): AGM voting results and fresh insider RSU awards draw investor attentio - AD HOC NEWS
Certara Shareholders Back Directors, Auditor and Executive Pay - TipRanks
Certara (CERT) reveals 2026 annual meeting director and proposal votes - Stock Titan
Certara (CERT) director converts 15,757 RSUs into common stock - Stock Titan
Certara (CERT) CFO Reynders gains shares as RSUs vest and new 33,222-unit grant awarded - Stock Titan
Certara (CERT) chairman adds 15,757 shares and 33,222 RSUs in equity awards - Stock Titan
Certara (CERT) director reports 5,547 shares from RSUs and 33,222 new RSUs - Stock Titan
Certara (CERT) chair exercises 15,757 RSUs and receives 33,222-unit grant - Stock Titan
Certara (NASDAQ: CERT) director adds shares through RSU vesting and new grant - Stock Titan
Certara (CERT) director Crane receives 15,757 shares from RSU vesting - Stock Titan
Certara (CERT) director adds 15,757 shares and receives 33,222 RSUs - Stock Titan
Law firm investigates Certara after Q1 revenue drop and 19% stock plunge - Pluang
CERTARA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
Certara stock (US1567671046): Q1 revenue up 1% but services decline sparks investigation - AD HOC NEWS
Earnings call transcript: Certara Q1 2026 results miss EPS forecast, stock drops - Investing.com
CERTARA, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud - The AI Journal
Certara (CERT) grants PSUs and RSUs to executive Robert Aspbury - Stock Titan
Certara (CERT) grants new PSUs and RSUs to President and Chief Commercial Officer - Stock Titan
Certara (CERT) CHRO granted performance and restricted stock units in new awards - Stock Titan
Certara (CERT) CEO Jon Resnick granted large RSU and PSU packages in Form 4 filing - Stock Titan
Certara (CERT) SVP and General Counsel awarded new PSU and RSU grants - Stock Titan
Certara (CERT) CFO awarded new performance and restricted stock units in long-term plans - Stock Titan
Certara, Inc. Stock 12‑Month Price Target Cut to $7.62, Implies 50% Upside - TradingView
Vanguard Group Inc. Has $104.98 Million Stake in Certara, Inc. $CERT - MarketBeat
Certara (CERT) Q1 2026 Earnings Call Transcript - AOL.com
CERT Maintains by BMO Capital -- Price Target Lowered to $6.00 - GuruFocus
CERT Maintained by Barclays -- Price Target Lowered to $6.50 - GuruFocus
Certara, Inc. Shareholders Are Encouraged to Reach Out to - GlobeNewswire
CERT Maintained by Craig-Hallum -- Price Target Lowered to $8.00 - GuruFocus
Craig-Hallum Maintains Certara(CERT.US) With Hold Rating, Announces Target Price $8 - Moomoo
CERT Maintained by Morgan Stanley -- Price Target Lowered to $10 - GuruFocus
Certara (NASDAQ:CERT) Given New $8.00 Price Target at Craig Hallum - MarketBeat
Certara Q1 2026 presentation: mixed results spark 17% stock drop By Investing.com - Investing.com Australia
CERT Maintained by Stephens & Co. -- Price Target Lowered to $9. - GuruFocus
BMO cuts Certara stock price target on execution risk concerns - Investing.com UK
BMO cuts Certara stock price target on execution risk concerns By Investing.com - Investing.com Nigeria
A Quick Look at Today's Ratings for Certara(CERT.US), With a Forecast Between $6 to $10 - Moomoo
CERT Maintained by Baird -- Price Target Lowered to $6.00 - GuruFocus
Morgan Stanley Cuts Certara (NASDAQ:CERT) Price Target to $10.00 - MarketBeat
Certara, Inc. (NASDAQ:CERT) Q1 2026 Earnings Call Transcript - Insider Monkey
Certara Inc Stock (CERT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Certara Inc Stock (CERT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Reynders John V W | Chief Financial Officer |
May 14 '26 |
Option Exercise |
0.00 |
15,757 |
0 |
26,466 |
| BROSHY ERAN | Chairman |
May 14 '26 |
Option Exercise |
0.00 |
15,757 |
0 |
50,708 |
| Bedi Arjun | Director |
May 14 '26 |
Option Exercise |
0.00 |
5,547 |
0 |
5,547 |
| CASHMAN JAMES E III | Chairman |
May 14 '26 |
Option Exercise |
0.00 |
15,757 |
0 |
484,197 |
| Killefer Nancy | Director |
May 14 '26 |
Option Exercise |
0.00 |
15,757 |
0 |
51,846 |
| Crane Rosemary A | Director |
May 14 '26 |
Option Exercise |
0.00 |
15,757 |
0 |
45,672 |
| WALSH MATTHEW M | Director |
May 14 '26 |
Option Exercise |
0.00 |
15,757 |
0 |
213,316 |
| Resnick Jon Matthew | Chief Executive Officer |
May 11 '26 |
Option Exercise |
0.00 |
59,766 |
0 |
59,766 |
| Pedersen Leif E | PRESIDENT, CHIEF COMMERCAL OFF |
Apr 01 '26 |
Option Exercise |
0.00 |
33,167 |
0 |
113,744 |
| McKemey Adrian | President, Drug Dev. Solutions |
Apr 01 '26 |
Option Exercise |
0.00 |
10,849 |
0 |
10,849 |
1.18%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):